DAVID SHIMM, M.D.; GERALD LOGUE, M.D.
This content is PDF only. Please click on the PDF icon to access.
The value of the randomized trial for the evaluation of new cancer therapies is undisputed. However, because such trials often do not accrue sufficient numbers of patients in a period of time short enough to be practical (especially when the disease under study is not particularly common), investigators often resort to alternatives to the randomized control group.
Several recently published clinical studies using chemotherapy for patients with solid tumors have reported survival data by comparing the actuarial survival of patients responding to chemotherapy to the survival of patients not responding to chemotherapy (1-3). Invariably, patients who respond survive longer than
SHIMM D, LOGUE G. Analysis of Survival in Cancer Clinical Trials. Ann Intern Med. 1983;98:665–666. doi: https://doi.org/10.7326/0003-4819-98-5-665
Download citation file:
Published: Ann Intern Med. 1983;98(5_Part_1):665-666.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use